Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2020 1
2021 1
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of the holistic, psychonutritional approach of Centro DAI e Obesità di Città della Pieve in the management of type 2 diabetes among patients with obesity and dysfunctional eating.
Barana L, Colleluori G, Sulpizi MT, Ortenzi K, Farano L, Fanelli CG, Calafiore R, Dalla Ragione L, Pampanelli S. Barana L, et al. Among authors: fanelli cg. J Diabetes Metab Disord. 2022 Jul 22;21(2):1883-1893. doi: 10.1007/s40200-022-01085-1. eCollection 2022 Dec. J Diabetes Metab Disord. 2022. PMID: 35891980 Free PMC article. Review.
Nutritional Management of Athletes with Type 1 Diabetes: A Narrative Review.
Cavallo M, De Fano M, Barana L, Dozzani I, Bianchini E, Pellegrino M, Cisternino L, Migliarelli S, Giulietti C, Pippi R, Fanelli CG. Cavallo M, et al. Among authors: fanelli cg. Nutrients. 2024 Mar 21;16(6):907. doi: 10.3390/nu16060907. Nutrients. 2024. PMID: 38542818 Free PMC article. Review.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Garber AJ, et al. Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0. Lancet. 2012. PMID: 22521072 Clinical Trial.